Circulating Methylated DNA as Biomarkers for Cancer Detection by Jin, Hongchuan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Circulating Methylated DNA as Biomarkers for Cancer
Detection
Hongchuan Jin, Yanning Ma, Qi Shen and
Xian Wang
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/51419
1. Introduction
In addition to genetic alterations including deletion or point mutations, epigenetic changes
such as DNA methylation play an important role in silencing tumor suppressor genes dur‐
ing cancer development. By adding a methyl group from S-adenosyl-L-methionine to the cy‐
tosine pyrimidine or adenine purine ring, DNA methylation is important to maintain
genome structure and regulate gene expression. In mammalian adult tissues, DNA methyla‐
tion occurs in CpG dinucleotides that often cluster in the genome as CpG islands in the 5’
regulatory regions of the genes. Through recruiting transcriptional co-repressors including
methyl-CpG-binding domain proteins (MBDs) and chromatin remodeling proteins like his‐
tone deacetylases (HDACs) or impeding the binding of transcriptional activators, DNA
methylation could suppress the transcription of many tumor suppressor genes critical to
cancer initiation and progression [1-3].
More and more results confirmed that cancer is a multi-stage process fuelled by many epige‐
netic changes in addition to genetic changes in DNA sequence [4]. Chemical molecules like
Trichostatin A (TSA) and 5-aza-2'-deoxycytidine (5-Aza-CdR) targeting epigenetic regula‐
tors such as histone modifications and DNMTs (DNA methyltransferases) have been found
to inhibit tumor growth both in vitro and in vivo. By reversing the epigenetic silencing of
important tumor suppressor genes, an increasing number of epigenetic drugs such as 5-Aza-
CdR, 5-Aza-CR and Vorinostat (SAHA) are currently investigated in the clinical trials for
cancer treatment as a single drug or in combination with other epigenetic drugs or other ap‐
proaches such as chemotherapy and showed very promising activities by offering signifi‐
cant clinical benefits to cancer patients [5-13].
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As one of the major epigenetic changes to inactivate tumor suppressor genes critical to hu‐
man cancer development, DNA methylation was recognized as the biomarker for cancer de‐
tection or outcome prediction in addition to the identification of novel tumor suppressor
genes. DNA mutations will occur randomly in any nucleotides of one particular gene and
the comprehensive determination of DNA mutations is thus very difficult and time-consum‐
ing. In contrast, aberrant DNA hypermethylation usually takes place in defined CpG Islands
within the regulatory region of the genes and it is much more convenient to detect DNA
methylation in a quantitatively manner. In addition, DNA methylation can be amplified and
is thus easily detectable using PCR-based approaches even when the DNA concentration af‐
ter sample extraction is relatively low. Due to such advantages over DNA mutation- or pro‐
tein-based biomarkers, DNA methylation-based biomarkers have been intensively
investigated in the recent years. A large body of research reports has proved the value of
DNA methylations in the prognosis prediction and detection of various cancers. DNAs used
for such methylation analyses are usually extracted from tumor tissues harvested after sur‐
gical operation or biopsy, thus limiting its wide application as the biomarkers for the early
detection or screening of human cancers. Recently, it has been reported that there are certain
amount of circulating DNAs in the peripheral blood of cancer patients, providing an ideal
source to identify novel biomarkers for non-invasive detection of cancers. Both genetic and
epigenetic changes found in the genomic DNAs extracted from primary tumor cells could be
detected in the circulating DNAs, indicating that the detection of methylated DNAs in the
circulation represents a new direction to develop novel biomarkers for cancer detection or
screening in a non-invasive manner.
2. Cell free DNA in the circulation
According to the origin of circulating tumor-related DNA, it could be grouped into circulat‐
ing cell free DNA or DNA from cells in the blood such as circulating tumor cells (CTC) in
cancer patients (Figure 1).
In 1869, the Australian physician Thomas Ashworth observed CTCs in the blood of a cancer
patient. Therefore, it was postulated that CTCs were responsible for the tumor metastases in
distal sites and should have important prognostic and therapeutic implications [14-16].
However, the number of CTCs is very small compared with blood cells. Usually around 1-10
CTCs together with several million blood cells could be found in 1 ml of whole blood, mak‐
ing the specific and sensitive detection of CTCs very difficult [17-18]. Until recently, technol‐
ogies with the requisite sensitivity and reproducibility for CTC detection have been
developed to precisely analyze its biological and clinical relevance. The US Food and Drug
Administration (FDA) approved the test for determining CTC levels in patients with meta‐
static breast cancer in 2004. Currently, it has been expanded to other cancer types such as
advanced colorectal cancer and prostate cancer. Although CTCs-counting based test have
proven its value in predicting prognosis and monitoring therapeutic effects, the number of
CTCs per ml of blood limited its sensitivity greatly [19]. With the development of high-sen‐
sitive PCR-based methods, the detection of gene mutations or epigenetic changes such as
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DNA methylation within small amount of CTCs could be the next generation of CTC-based
test for cancer detection. However, the cost of such tests will be greatly exacerbated, thus
limiting its wide application in the clinic [20-22].
Figure 1. Circulating tumor cells and cell free DNA. Circulating Tumor cells (CTC) escape from primary sites and spread
into the vessel to form metastases in the distal organs with. Cell free DNAs (cf-DNAs) are released into the circulation
from dead cancer cells or proliferating tumor cells. RBC: red blood cell; WBC: white blood cell.
Although its origin and biological relevance remains unknown, circulating cell free DNA (cf-
DNA) is supposed to be valuable source to identify cancer markers with ideal sensitivity and
specificity for non-invasive detection of cancer [23-24]. Early in 1948, two French scientists
Mandel and Metais firstly reported the presence of cf-DNAs in human plasma [25]. Such an
important discovery has been unnoticed for a long time until cell-free circulating nucleic acid
was found to promote the spread and metastasis of crown gall tumor in plants [26]. Subse‐
quently, increased level of cf-DNAs was found in patients with various diseases such as lupus
erythematosus and rheumatoid arthritis cancer [27-28]. In 1977, Leon et al. reported that higher
level of circulating DNA in the plasma of cancer patients when compared to healthy con‐
trols. Moreover, greater amounts of cf-DNA were found in the peripheral blood of cancer
patients with tumor metastases and cf-DNA levels decreased dramatically after radiothera‐
py while persistently high or increasing DNA concentrations were associated with a lack of
response to treatment [29], clearly revealing the potential value of cf-DNA as biomarker for
cancer detection. Following studies confirmed that cf-DNAs in the plasma contains genetic
and epigenetic changes specific to DNAs within the tumor cells from primary tissues, indicat‐
ing that tumor specific cf-DNAs are originated from tumor cells rather than lymphocytes
reacting towards the disease [30-31]. For example, K-Ras mutation was found in cf-DNA from
17 out of 21 patients with pancreatic adenocarcinoma and mutations were similar in corre‐
sponding plasma and tissues samples. Importantly, such DNA alterations were found in
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patients with pancreatitis who were diagnosed as pancreatic cancer 5-14 months later, indi‐
cating that release of tumor-specific DNA into the circulation is an early event in cancer
development and cf-DNA could be used as the biomarkers for early cancer detection [32].
Treatment resulted in disappearance of K-Ras mutations in plasma DNA in six of nine pa‐
tients. Three patients with a persistently positive K-Ras gene mutation in plasma samples from
patients before and after treatment showed early recurrence or progression and pancreatic
carcinoma patients with the mutant-type K-ras gene in plasma DNA exhibited a shorter survival
time than patients with the wild-type gene, indicating the cf-DNA could be of value in monitoring
disease progression or evaluating treatment response [31, 33].
Through quantitatively analyzing plasma DNAs from patients with organ transplantation,
Lo et al found that the majority of plasma DNAs was released from the hematopoietic sys‐
tem. However, donor DNA could be detected in the plasma of recipients suffering from the
graft rejection because of the large amount of cell death which promotes the release of donor
DNAs into the peripheral blood of the recipients [34]. Therefore, it was postulated that cell-
free tumor related DNA could originate from the apoptotic tumor cells since high-rate of
apoptosis indeed occurs in primary and metastatic tumor tissues. However, cf-DNA quanti‐
ties are significantly reduced in cancer patients after radiotherapy when a great number of
tumor cells were believed to undergo apoptotic cell death and cf-DNAs in supernatants of
cultured cancer cells increases with cell proliferation rather than apoptosis or necrosis, indi‐
cating that proliferating tumor cells could actively release cf-DNA into the tumor microen‐
vironment and circulation.
In contrast to labile RNAs that were included into the actively secreted exosomes, the nature
of cf-DNAs remains to be clarified. As negatively charged molecules, cf-DNA was bound by
plasma proteins to escape from endonuclease-mediated degradation. Unfortunately, plasma
proteins bound to cf-DNAs was not well characterized yet. Meanwhile, secreted exosomes
could remodel microenviroments and promote tumor metastasis since RNAs within exo‐
somes especially microRNA with high stability may influence gene expression in neighbor
cells. The biological relevance of cf-DNAs remains unknown. DNA was believed to be more
structural rather than functional. However, it was supposed that cf-DNA could play a role
as vaccine in tumor microenvironment.
3. Methods for the detection of methylated DNA
It is unclear so far whether serum or plasma is better for cf-DNA extraction. Although the
DNA amount is significantly higher in the serum, the majority of the increase was due to the
release of nuclear acids from destroyed blood cells during blood clotting [35]. In addition,
the time gap between blooding drawing and DNA extraction as well as the methodologies
used for DNA isolation contribute greatly to the amount of cf-DNA harvested. On an aver‐
age, around 30 ng cf-DNA could be extracted from one ml of blood sample [36]. Therefore,
in order to determine the quantity of potential cf-DNA-based biomarkers precisely and pro‐
mote its wide application for cancer detection, it is very important to unify the source as
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well as the methodologies for cf-DNA extraction and use various internal controls to adjust
possible inter-laboratory variations.
Figure 2. Schematic introductions of various methods for methylation analyses. MSP, BGS and COBRA are based on
bisulfite-mediated conversion of unmethylated cytosines into uracils. CpG methylation could block DNA digestion by
some restriction enzymes, making it possible to determine methylation status independent of bisulfite treatment by
analyzing digestion products. Alternatively, DNA fragments containing methylated CpG sites could be enriched by an‐
ti-methylcytosine antibody or methylation binding proteins. Advances in next generation genome sequencing tech‐
nology led to the development of noel techniques such as SMRT which can specially analyze 5-methylcytosines with
genome wide coverage.
In general, the detection of DNA methylation could be bisulfite-dependent or -independent
(Figure 2).
The chemical reaction of sodium bisulfite with DNA could convert unmethylated cytosine
of CpG into uracil or UpG but leave methylated cytosine of CpG unchanged. The following
analyses such as methylation-and unmethylation specific polymerase chain reaction (M- and
U-SP), bisulfite genome sequencing (BGS) or combined bisulfite restriction analysis (CO‐
BRA) could determine the conversion of CpG sites of interest, thus reflecting their methyla‐
tion status as methylated or unmethylated [37]. With varied resolution levels, different
bisulfite-dependent DNA methylation analysis methods detect the conversion after bisulfite
treatment of genomic DNA, which could have certain artificial effects such as incomplete
conversion of unmethylated CpG into UpG, leading to high rate of false negative conclusion
of DNA methylation status.
Recently, some new modifications of cytosine in CpG dinucleotides have been discovered
such as 5-hydoxymethylcytosine which was called the sixth base since 5-methylcytosine was
named as the fifth base [38]. Generated from the oxidation of 5-methylcytosine by the Tet
family of enzymes, 5-hydoxymethylcytosine was first found in bacteriophages and recently
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shown to be abundant in human and mouse brains as well as in embryonic stem cells
[39-40]. Although the exact relevance of 5-hydoxymethylcytosine in the genome is still not
fully clarified, it has been found to regulate gene expression or promote DNA demethyla‐
tion. The in vitro synthesized artificial oligonucleotides containing 5-hydoxymethylcyto‐
sines can be converted into unmodified cytosines when introduced into mammalian cells,
indicating that 5-hydoxymethylcytosine might be one of intermediate products during ac‐
tive DNA demethylation [41]. Therefore, the increase of 5-hydoxymethylcytosine might re‐
flect the demethylation of CpG dinucleotides. Unfortunately, 5-hydoxymethylcytosines,
similar to 5-methylcytosines, appear to be resistant to bisulfite-mediated conversion and
PCR could amplify DNA fragments containing 5-hydoxymethylcytosines or 5-methylcyto‐
sines with similar efficiency [42-43]. Therefore, bisulfite-dependent methylation analyses
could produce false positive results by counting 5-hydoxymethylcytosines into 5-methylcy‐
tosines. In addition to 5-hydroxymethylcytosines, some forms of DNA modifications such as
the seventh base, 5-formylcytosine and the eighth base, 5-carboxylcytosine, have been found
in mammalian cells recently [44-47]. As the products of 5-hydoxymethylcytosine oxidation
through TET hydroxylases, both 5-formylcytosine and 5-carboxylcytosine will be read as the
uracil after bisulfite conversion, thus making it impossible for bisulfite-dependent analyses
to distinguish unmodified cytosines from 5-formylcytosines and 5-carboxylcytosines.
Bisulfite independent analyses such as MedIP (methylated DNA immunoprecipitation)
could more or less detect DNA methylation specifically. In bisulfite independent analyses, 5-
methylcytosines are differentiated from unmethylated cytosine by either enzyme digestion
or affinity enrichment. DNA methylation analysis using restriction enzyme digestion is
based on the property of some methylation-sensitive and -resistant restriction enzymes such
as HpaII and MspI that target CCGG for digestion. HpaII fails to cut it once the second cyto‐
sine was methylated while MspI-mediated digestion is not affected by DNA methylation,
thus making it possible to determine the methylation status of CpG in the context of CCGG
tetranucleotides by analyzing the products of DNAs digested by HpaII and MspI respective‐
ly. As a primary method to analyze DNA methylation, it can only determine the methyla‐
tion of CpG in the context of CCGG tetranucleotides and will overlook the majority of CpG
dinucleotides in the genome.
The development of monoclonal antibody specific to 5-methylcytosines revolutionized the
analyses of DNA methylation [48-49]. Immunoprecipitated DNA by this antibody could be
subject to DNA microarray or even deep sequencing to reveal novel sequences or sites con‐
taining 5-methylcytosines [50]. This antibody specifically recognizes 5-methylcytosines but
not 5-hydoxymethylcytosines. However, 5-methylcytosines could present not only in CpG
dinucleotides but also in CHH or CHG trinucleotides, especially in plants, human embryon‐
ic stem cells and probably cancer cells as well. CHH methylation indicates a 5-methylcyto‐
sine followed by two nucleotides that may not be guanine and CHG methylation refers to a
5-methylcytosine preceding an adenine, thymine or cytosine base followed by guanine. Such
non-CpG DNA methylations were enriched at transposons and repetitive regions, although
the exact biological relevance remains unknown. However, antibody against 5-methylcyto‐
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sine may precipitate methylated CHH and CHG trinucleotide containing DNA fragments in
addition to DNA sequences with methylated CpG sites.
DNA methylation functions as the signal for DNA-interacting proteins to maintain genome
structure or regulate gene expression. The proteins such as MBD1 (methyl-CpG binding do‐
main protein 1), MeCP2 (methyl CpG binding protein 2) and MBD4 (methyl-CpG binding
domain protein 4) bind methylated CpG specifically to regulate gene expression [51-52].
Therefore, methyl-CpG binding domain could specifically enrich differentially methylated
regions (DMRs) of physiological relevance [53]. Similar to MeDIP, MBD capture specifically
enrich methylated CpG sites rather than hydroxymethlated CpG sites. The detailed analysis
to compare MeDIP and MBD capture revealed that both enrichment techniques are sensitive
enough to identify DMRs in human cancer cells. However, MeDIP enriched more methylat‐
ed regions with low CpG densities while MBD capture favors regions of high CpG densities
and identifies the greater proportion of CpG islands [49].
Recently, the advance of next generation sequencing led to the development of several novel
techniques, making it possible to quantitatively analyze DNA methylation at single nucleo‐
tide resolution with genome wide coverage. Both the single molecule real time sequencing
technology (SMRT) and the single-molecule nanopore DNA sequencing platform could dis‐
criminate 5-methylcytosines from other DNA bases including 5-hydroxymethylcytosines
even methyladenine independent of bisulfite conversion [54-55]. With many advantages
such as less bias during template preparation, lower cost and better accuracy, such new
techniques could offer more methods to detect DNA methylation with high specificity and
sensitivity in addition to more potential DNA methylation based biomarkers for cancer de‐
tection and screening.
4. Potential DNA methylation biomarkers for cancer detection
It has been questioned whether the methylated DNA in the circulation is sensitive to detect
cancers early enough for curative resection. However, the development of sensitive detection
methods confirmed the potential value of DNA methylation in cancer detection (Table 1).
Most of DNA methylation biomarkers are well-known tumor suppressor genes silenced in
primary tumor tissues. However, the biomarks do not have to be functional relevant. For ex‐
ample, currently well-used biomarkers such as AFP (Alpha-Fetal Protein), PSA (Prostate-
specific antigen) and CEA (Carcinoembryonic antigen) are not tumor suppressor genes with
important biological functions. Profiling of methylated DNA in the circulation instead of
primary tumor tissues with MeDIP or MBD capture or other methylation specific analyses
methods would identify more potential biomarks rather than functional important tumor
suppressor genes.
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Cancer Markers Sensitivity Specificity Methods Ref.
Bladder cancer CDKN2A (ARF) CDKN2A
(INK4A)
CDKN2A (INK4A)
13/27 (48%)
2/27 (7%)
19/86 (22%)
N/A
N/A
31/31 (100%)
MSP
MSP
MSP
[58]
 
[59]
Breast cancer CDKN2A (INK4A)
 
CDKN2A (INK4A)
5/35 (14%)
 
6/43 (14%)
N/A
 
N/A
MS-AP-
PCR
MS-AP-
PCR
[56]
 
[57]
Colorectal cancerMLH1
CDKN2A (INK4A) CDKN2A
(INK4A) CDKN2A (INK4A)
ALX4
CDH4
NGFR
RUNX3
SEPT9
TMEFF2
3/18 (17%)
14/52 (27%)
13/94 (11%)
21/58 (36%)
25/30 (83%)
32/46 (70%)
68/133 (51%)
11/17 (65%)
92/133 (69%)
87/133 (65%)
N/A
44/44 (100%)
N/A
N/A
36/52 (70%)
17/17 (100%)
150/179 (84%)
10/10 (100%)
154/179 (86%)
123/179 (69%)
MSP
MSP
MSP
MSP
MSP
MSP
MSP
MSP
MSP
MSP
[60]
[61]
[62]
[63]
[64]
[65]
[66]
[67]
[66]
Esophageal
cancer
APC
APC
CDKN2A (INK4A)
13/52 (25%)
2/32 (6%)
7/38 (18%)
54/54 (100%)
54/54 (100%)
N/A
MSP
MSP
MSP
[68]
 
[69]
Gastric cancer CDH1
CDKN2A (INK4A)
CDKN2B (INK4B)
DAPK1
GSTP1
Panel of five
31/54 (57%)
28/54 (52%)
30/54 (56%)
26/54 (48%)
18/54 (15%)
45/54 (83%)
30/30 (100%)
30/30 (100%)
30/30 (100%)
30/30 (100%)
30/30 (100%)
30/30 (100%)
MSP
MSP
MSP
MSP
MSP
MSP
[70]
Head and neck
cancer
CDKN2A (INK4A)
DAPK1
MGMT
Panel of three
DAPK1
8/95 (8%)
3/95 (3%)
14/95 (15%)
21/95 (22%)
N/A
N/A
N/A
N/A
N/A
N/A
MSP
MSP
MSP
MSP
MSP
[71]
 
 
 
[72]
Liver cancer CDKN2A (INK4A) CDKN2B
(INK4B)
13/22 (45%)
4/25 (16%)
48/48 (100%)
35/35 (100%)
MSP
MSP
[73]
[74]
Lung cancer CDKN2A (INK4A)
DAPK1
GSTP1
MGMT
Panel of four
CDKN2A (INK4A)
APC
3/22 (14%)
4/22 (18%)
1/22 (5%)
4/22 (18%)
11/22 (50%)
N/A
42/89 (47%)
N/A
N/A
N/A
N/A
N/A
N/A
50/50 (100%)
MSP
MSP
MSP
MSP
MSP
MSP
MSP
[75]
 
 
 
 
[76]
[77]
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Cancer Markers Sensitivity Specificity Methods Ref.
CDKN2A (INK4A)
CDKN2A (INK4A)
77/105 (73%)
12/35 (34%)
N/A
15/15 (100%)
MSP
MSP
[78]
[79]
Prostate cancer GSTP1
GSTP1
23/33 (70%)
25/69 (36%)
22/22 (100%)
31/31 (100%)
MSP
MSP
[80]
[81]
Table 1. Methylated DNA biomarkers in the literature.
Most of the methods used for methylation biomarkers analyses are still bisulfite dependent.
Few reports used MS-AP-PCR (methylation-sensitive arbitrarily primed PCR) which takes
the advantage of methylation sensitive restriction endonucleases to distinguish methylated
CpG from unmethylated form, although the sensitivity seems to be lower than MSP [56-57].
Interestingly, combination of more than one methylated DNA as a methylation panel could
great increase the sensitivity for cancer detection without significant reduction of specificity.
Unfortunately, most of studies were performed in a retrospective manner. More prospective
studies with large sample sizes will be warranted to compare different approaches especial‐
ly bisulfite-independent methods in addition to confirm the value of DNA methylation for
cancer detection.
5. Conclusion and Perspectives
With the development of the next generation genome sequencing as well as single molecular
PCR, it became possible to analyze trace amount of DNAs including circulating cell-free
DNA. Circulating tumor cells have been proven its value in prognosis predication even ear‐
ly detection of various cancers. The analyses of methylated DNAs in the circulating will be
the next promising epigenetic biomarkers for cancer detection. As one of the intermediate
products of DNA demethylation, 5-hydroxymethlcytosines are resistant to bisulfite conver‐
sion. Therefore, it should be carefully to interpret the data of methylation analyses based on
bisulfite treatment due to potentially high rate of false positive results. Although some me‐
thylated DNAs were found to valuable as a single biomarker for cancer detection, more po‐
tential DNA methylations will be found after the wide application of SMRT and other
sequencing platforms with high speed, depth and accuracy. DNA methylation signatures in‐
cluding a panel of methylated DNAs will show the potential in the early diagnosis or
screening and prognosis or therapy response prediction of many cancers. In addition, such
DNA methylation biomarkers could be more sensitive and specific for cancer detection
when combined with well-used biochemical biomarkers. However, unified methods with
gold standards will be warranted to promote the development and clinical application of
DNA methylation biomarkers.
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